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ABSTRACT
Rheumatoid Arthritis (RA) is an autoimmune disorder that results in inflamed joints and
osteoporosis.

Previous

studies

have

shown

that

Mycobacterium

avium

subspecies

Paratuberculosis (MAP) has a role in the downregulation of active osteocalcin in Crohn’s disease
(CD). Since RA and CD have a similar pathology, we hypothesize that active inflammation
following MAP infection will result in downregulation of active osteocalcin in RA patients. In this
study, a total of 82 individuals (48 RA and 34 healthy) were examined for MAP status and for
active osteocalcin. Out of the 48 RA patients, 18 were MAP positive compared to only 1 out of 34
healthy control (P-values < 0.05). Overall, active osteocalcin levels between RA (2.70 ± 0.87
ng/mL) were significantly lower than healthy controls (5.84 ± 1.42 ng/mL, P-values < 0.05). MAP
positive RA patients active osteocalcin levels were lower (0.60 ± 0.31 ng/mL) than MAP negative
RA patients (3.85 ± 1.31 ng/mL). The active osteocalcin level in healthy MAP positive controls
were lower (1.65 ng/mL) than healthy MAP negative controls (5.96 ± 1.45 ng/mL). The level of
active osteocalcin in all MAP positive patients was significantly lower (0.66 ± 0.29 ng/mL) than
all MAP negative patients (4.95 ± 0.98 ng/mL, P-values < 0.05). The correlation between presence
of MAP in RA individuals and downregulation of active osteocalcin supports a role of MAP as a
pathogenic element in RA.
In addition, we tested three Single Nucleotide Polymorphisms (SNPs) in TNFα,
TNFRSF1A and TNFRSF1B by TaqMan genotyping from peripheral blood samples of the 82
subjects. These SNPs were used to determine whether they influence the levels of osteocalcin in
RA and healthy patients. Patients with the SNP TNFRSF1B:rs3397 who had TT genotype had a
significantly lower osteocalcin level compared with patients without SNP who had CC genotype
(0.98 ± 0.35 ng/mL vs. 1.86 ± 0.61 ng/mL). Overall, there was a correlation of the presence of
these SNPs and the downregulation of osteocalcin in RA.
iii

ACKNOWLEDGMENTS

First and foremost, I’d like to thank Almighty God for giving me the chance of being. I
am grateful for the countless bounties he’s bestowed upon me. I pray that this humble effort of
mine may become of benefit to my fellow humans.
Second; I’d like to offer my deepest gratitude to Dr. Saleh Naser for his enduring
patience, everlasting encouragement, and enlightened guidance during the last years. Dr. Naser
was an inspirational role model. I’d also like to thank the elite Thesis Committee, Dr. Samsam
and Dr. Yooseph for their guidance, vision, and encouragement.
I also would like to take this opportunity to express my indebtedness to all my friends and
coworkers for their great assistance with this study.
I wish if I can give individual acknowledgment to all those who had contributed
somehow to this work, but I can’t, so I am truly grateful to each and every one who has
participated by any means to this study. Your contributions are highly appreciated.
Ahmad K Odeh

iv

TABLE OF CONTENTS
LIST OF TABLES ............................................................................................................................... vii
LIST OF ACRONYMS/ ABBREVIATIONS .......................................................................................... viii
CHAPTER 1. INTRODUCTION ........................................................................................................... 1
1.1

Introduction...................................................................................................................... 1

1.1.1 Rheumatoid Arthritis .................................................................................................... 1
1.1.2 Crohn’s Disease ............................................................................................................ 2
1.1.3 Tumor Necrosis Factor-α and Single Nucleotide Polymorphisms ................................ 4
1.2

Research Intent and Objective ......................................................................................... 7

1.3

Research Hypothesis ........................................................................................................ 7

CHAPTER 2. RESEARCH METHODOLOGY ........................................................................................ 8
2.1

Detection of MAP infection in RA patients and healthy controls .................................... 8

2.2

Quantifying active osteocalcin level in RA patients and healthy controls ....................... 9

2.3

Identification of SNPs in TNFα, TNFRSF1A, and TNFRSF1B genes ................................. 10

CHAPTER 3. RESULTS..................................................................................................................... 11
3.1

MAP and Osteocalcin ..................................................................................................... 11

3.2

SNPs and Osteocalcin ..................................................................................................... 13

CHAPTER 4. DISCUSSION............................................................................................................... 17
CHAPTER 5. CONCLUSIONS AND FUTURE DIRECTIONS ................................................................ 18
LIST OF REFERENCES ..................................................................................................................... 19
v

LIST OF FIGURES
Figure 1-1: Mechanism of Bone Demineralization ........................................................................ 5
Figure 2-1: Step-by-step process of ELISA sandwich formation ................................................... 9
Figure 3-1: Column graph of Average Active Osteocalcin levels for RA and Healthy patients .. 11
Figure 3-2: Column graph of Average Active Osteocalcin levels for MAP- vs. MAP+ patients 12
Figure 3-3: Column graph of Average Active Osteocalcin levels for MAP- vs. MAP+ in RA and
MAP- vs. MAP+ in Healthy patients ............................................................................................ 13
Figure 3-4: Column graph of Average Active Osteocalcin levels for Healthy and RA patients
with TNFα:rs1800629................................................................................................................... 14
Figure 3-5: Column graph of Average Active Osteocalcin levels for Healthy and RA patients
with TNFR1:rs767455 .................................................................................................................. 15
Figure 3-6: Column graph of Average Active Osteocalcin levels for Healthy and RA patients
with TNFR2:rs3397 ...................................................................................................................... 16

vi

LIST OF TABLES
Table 1-1: Gene mutations, location, and mutation phenotypes of SNPs selected for this study .. 6
Table 1-2: Genotype frequencies of selected SNPs for patients with RA and healthy controls ..... 6
Table 2-1: Primers and amplification conditions used for PCR ..................................................... 8
Table 3-1: Average Active Osteocalcin levels for RA and Healthy patients ............................... 11
Table 3-2: Average Active Osteocalcin levels for MAP- vs. MAP+ patients .............................. 12
Table 3-3: Average Active Osteocalcin levels for MAP- vs. MAP+ in RA and MAP- vs. MAP+
in Healthy patients ........................................................................................................................ 13
Table 3-4: Average Active Osteocalcin levels for Healthy and RA patients with
TNFα:rs1800629 ........................................................................................................................... 14
Table 3-5: Average Active Osteocalcin levels for Healthy and RA patients with
TNFR1:rs767455 .......................................................................................................................... 15
Table 3-6: Average Active Osteocalcin levels for Healthy and RA patients with TNFR2:rs3397
....................................................................................................................................................... 16

vii

LIST OF ACRONYMS/ ABBREVIATIONS
CD

Crohn’s Disease

DNA

Deoxyribonucleic Acid

DMARDs

Disease Modifying Anti-Rheumatic Drugs

ELISA

Enzyme-Linked Immunosorbent Assay

IBD

Inflammatory Bowel Disease

MAP

Mycobacterium Avium subspecies Paratuberculosis

nPCR

Nested Polymerase Chain Reaction

RA

Rheumatoid Arthritis

RT-PCR

Reverse Transcription Polymerase Chain Reaction

SNPs

Single Nucleotide Polymorphisms

TNF-α

Tumor Necrosis Factor-α

TNFR1

Tumor Necrosis Factor Receptor 1

TNFRS1A

TNF Receptor Superfamily Member 1A (TNFRS1A)

TNFRS1B

TNF Receptor Superfamily Member 1B (TNFRS1A)

USA

United States of America

viii

CHAPTER 1. INTRODUCTION
1.1 Introduction
1.1.1

Rheumatoid Arthritis

Rheumatoid Arthritis (RA) is a chronic, systemic autoimmune disease involving synovial
inflammation and degeneration of joints [1]. RA changes the biomechanical properties of bones
and alterations of bone structure through the increased production of pro-inflammatory cytokines
[2]. The inflammation of RA not only affects joints, but it affects the internal organs and systems
of the body, such as the respiratory system, circulatory system, skin, skeletal system, heart, lungs,
kidneys, blood vessels, and brain [3]. Demographically, RA can affect anyone regardless of race,
gender, and age. RA does not have any correlation with seasonal patterns nor socio-economic
living conditions [4]. While there is no definitive treatment for RA, therapy and medications can
help decrease the progression of the disease. For example, Disease Modifying Anti-Rheumatic
Drugs (DMARDs) have been shown to decrease inflammation and slow radiographic progression,
but the extent to its success is still unknown [5]. Although it decreases the inflammation, it is
known to be an immunosuppressant, thus increasing the risk of infection [6].
Patients diagnosed with RA are at higher risk of osteoporosis, which is a disease
characterized by dysregulation of bone formation and breaking leading to more porous bone and
greater risk of fracture [7]. There is a high risk of fracture in those with osteoporosis as a result of
low bone mass, structural deterioration, and porous bone [8]. The lifetime risk of osteoporotic
fractures in women is 40-50% and in men is 13-22% [9]. The reason why the lifetime risk of
osteoporotic fractures in women is that high is most likely because of the decrease in estrogen
level as they age [10]. Deficiency of vitamin K, or calcium, and a decreased level of osteoblastic
production results in the presence of osteoporosis.
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Osteoporosis results in a decreased level of osteocalcin, a noncollagenous protein that is
specific to bone tissue formation and produced by osteoblasts [11]. As shown in Figure 1-1, the
deficiency of vitamin K or calcium results in a decreased level of bone creation, thus, the presence
of osteoporosis [12]. Osteocalcin serves as a good biomarker for bone growth when bone
resorption and formation are coupled [13]. Bone demineralization in RA individuals results from
the low amount of synthesis of active osteocalcin in the body. It is an important vitamin K
dependent bone formation protein that is secreted by osteoblasts [11, 12]. Osteocalcin plays a
major role in the regulation of metabolism in the body and in the formation of bone tissue [14]. In
addition, deficiency of vitamin K induces the production of the inactive form of osteocalcin,
known as undercarboxylated osteocalcin (ucOC) and the termination of active osteocalcin [15].
The undercarboxylated form of osteocalcin has a hormonal function that has been shown to affect
insulin sensitivity in glucose metabolism in mice [14]. Vitamin K is required for the synthesis of
the Y-carboxylation of osteocalcin [15]. Deficiency of vitamin K would result in a decreased level
of osteocalcin in the circulation which would lead to bone resorption and low glucose metabolism
[15]. Hence, in metabolism, the active form of osteocalcin is undercarboxylated osteocalcin and
the active form of osteocalcin in serum is Y-carboxylated osteocalcin [16]. As a result of there
being a decreased level of Y-carboxylated osteocalcin in the circulation in those that present with
osteoporosis, since RA and osteoporosis are associated with one another, individuals diagnosed
with RA will have a lower than normal amount of Y-carboxylated osteocalcin in their circulation.
1.1.2

Crohn’s Disease

Crohn’s disease (CD) is a chronic inflammatory bowel disease that can affect the entire
gastrointestinal tract from the mouth to the anus [17]. As of 2018, it is estimated that about 1.5
million people suffer from Inflammatory Bowel Disease (IBD) which causes considerable
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mortality, suffering, and economic loss every year [18]. The annual incidence of CD in North
America is reported to be 3.1-20.2 per 100,000 with a prevalence of 201 per 100,000 population
[18]. The etiology of CD has been subjected to be of various factors. CD’s exact etiology has been
unknown, but it is a complex interaction between genetic dispositions, environmental risk factors,
and immune dysregulation to intestinal microbiota [19]. Between genetic dispositions and
environmental risk factors, environmental factors have attributed to the rising incidence of CD
worldwide [20, 21]. Some examples of environmental risk factors that have influenced CD are
bacterial suspects, such as some strains of Escherichia coli and Mycobacterium avium subspecies
paratuberculosis (MAP) [22, 23]. MAP has been detected in very high numbers in the food chain
[22] and water supply, maternal-fetal transmission in human milk [24], and from the blood of
patients with CD [25, 26]. The pathogenesis of CD is also very dependent on the overproduction
of pro-inflammatory cytokines such as TNF-a and IFN-Y. These pro-inflammatory cytokines
promote chronic inflammation, increased granuloma formation, and increased apoptosis of
intestinal tissues [27, 28].
A study has been done in CD diagnosed human and bovine samples to determine whether
there was a correlation between MAP infection and bone turnover and their Y-carboxylated
osteocalcin, undercarboxylated osteocalcin (ucOC), and blood calcium levels [29]. It was
determined that following MAP infection, the average level of Y-carboxylated osteocalcin
decreased and the average level of ucOC increased in the human samples [29]. This suggested that
as a result of MAP infection, these CD patients would be at a higher risk of bone demineralization.
In RA individuals, there is a deficiency of vitamin K in their bone tissue which leads to a decrease
in osteoblast activity. A decrease in osteoblast activity would then lead to less synthesis of
osteocalcin which, hence, leads to bone demineralization in these individuals. Since CD and RA
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are both autoimmune diseases that share this similar pathology, we hypothesize that active
inflammation following MAP infection will result in downregulation of active osteocalcin in RA
patients.
1.1.3

Tumor Necrosis Factor-α and Single Nucleotide Polymorphisms

Tumor Necrosis Factor-α (TNF-α) is a significant proinflammatory cytokine that has been
found to play a pivotal role in the inflammation and bone degradation of individuals with CD and
RA. Patients that have been diagnosed with RA have shown elevated levels of TNF-α in their
synovial joints, which leads to the presence of fibroblast-like synoviocytes, macrophages,
chondrocytes, and osteoclasts [30]. Also, some patients that have been diagnosed with CD have
shown increased levels of mucosal TNF-α and elevated cell production of TNF-α [31]. TNF-α is
known to have a similar signaling pathway to the activation of the transcription factor Nuclear
Factor Kappa B (Nf-kappa B) of the apoptotic pathway [32]. TNF-α is known to be derived from
macrophages, but it can also come from lymphoid cells, mast cells, neurons, endothelial cells,
fibroblasts, and cardiac myocytes [33]. TNF-α has two receptors it binds to in order to influence
its inflammatory effects on cells: Tumor Necrosis Factor Receptor 1 (TNFR1), made by the TNF
Receptor Superfamily Member 1A (TNFRS1A) gene and Tumor Necrosis Factor Receptor 2
(TNFR2), made by the TNF Receptor Superfamily Member 1B (TNFRS1B) gene [34].
There has been a link between TNF-α and osteoclasts that supports a role for TNF-α’s
degradative role in bone tissue. Osteoclastogenesis was induced in bone marrow macrophages
(BMMs) by macrophage colony-stimulating factor (M-CSF) and Receptor Activator of Nuclear
Factor Kappa-Β Ligand (RANKL) by or without TNF-α [35]. The results found that TNF-α alone
could not induce osteoclastogenesis of BMMs without the combination of RANKL [35]. However,
previous studies were done that suggested that TNF-α could increase the production of
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osteoclastogenic cytokines such as M-CSF and RANKL, which would be induced in osteoblastlike cells and stimulate bone resorption [35]. Another study looked at the if single nucleotide
polymorphisms (SNPs) in TNFR1 led to an increase in production of osteoclasts or increase in
activity of osteoclasts [36]. The results of this study suggested that, pretreated with RANKL,
TNFR1 induces strong osteoclastogenesis, and the deletion of TNFR1 repudiates this response
[36].
Single nucleotide polymorphisms (SNPs) are variations in a single nucleotide that occur at
a specific position in the genome. The SNPs selected for this study in, TNFα, TNFRSF1, and
TNFRSF1B, were previously investigated among patients with CD and healthy controls. As shown
in Table 1-1, patients that had the TNFα:rs1800629 SNP had a higher susceptibility to CD. The
TNFR1:rs767455 SNP found in patients was used to predict anti-TNFα response in CD. The third
SNP selected, TNFR2:rs3397, was also used to predict anti-TNFα response in CD. Table 1-2
shows the genotypic frequencies of the selected SNPs for both RA and healthy patients. The
frequency of the following SNPs, TNFα:rs1800629, TNFR1:rs767455, and TNFR2:rs3397 were
investigated among patients with RA in comparison to healthy controls to determine whether or
not they influence the levels of osteocalcin in RA and healthy patients.

Figure 1-1: Mechanism of Bone Demineralization
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Table 1-1: Gene mutations, location, and mutation phenotypes of SNPs selected for this study

Table 1-2: Genotype frequencies of selected SNPs for patients with RA and healthy controls

6

1.2 Research Intent and Objective
The aim and objective of this thesis is to use a sandwich Enzyme-Linked Immunosorbent
Assay (ELISA) assay to measure the concentration of active osteocalcin in MAP positive and MAP
negative healthy patients and MAP positive and MAP negative RA patients.

1.3 Research Hypothesis
Active inflammation following MAP infection will result in downregulation of active
osteocalcin in RA patients.
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CHAPTER 2. RESEARCH METHODOLOGY
2.1 Detection of MAP infection in RA patients and healthy controls
A total of 82 individuals were examined for MAP status and active osteocalcin level. 48 of
the 82 individuals were diagnosed with RA and the remaining 34 individuals were healthy. To
detect for MAP infection, Deoxyribonucleic Acid (DNA) was extracted from blood samples of the
48 RA and 34 healthy individuals. Nested Polymerase Chain Reaction (nPCR) was performed in
order

to

amplify

the

MAP-

specific

insertion

sequence

IS900.

P90

(GTTCGGGGCCGTCGCTTAGG) and P91 (GAGGTCGATCGCCCACGTGA) primers were
used as the first round of amplification at the following conditions: 95 °C for 5 min, then 34 cycles
of 95 °C for 1 min, 58 °C for 1.5 min, 72 °C for 1.5 min. Final extension of 10 min at 72 °C. 398
bp was the product size amplified from this round. A second round of amplification was followed,
which

involved

using

AV1

(ATGTGGTTGCTGTGTTGGATGG)

and

AV2

(CCGCCGCAATCAACTCCAG) primers at the following conditions: 95 °C for 5 min, then 34
cycles of 95 °C for 1 min, 58 °C for 1.5 min, 72 °C for 1.5 min. Final extension of 10 min at 72
°C. The final product size amplified from this round was 298 bp.
Table 2-1: Primers and amplification conditions used for PCR
Source: Qasem, A et al. (2016). Oxidative stress due to MAP infection upregulates selenium-dependent
GPx activity. Gut pathogens, 8(1), 12.
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2.2 Quantifying active osteocalcin level in RA patients and healthy controls
ELISA sandwich assay was used to measure levels of active osteocalcin. Samples were
measured using Life Technologies Osteocalcin Human ELISA Kit (Life Technologies, Carlsbad,
California, USA) following manufacturer instructions. All the samples and reagents were set to
room temperature. 25 µL of six different concentrations of standards were provided and added to
a pre-coated plate along with samples and controls. After the 25 µL of six different concentrations
of standards were added, 100 µL of Anti-osteocalcin-horseradish peroxidase enzyme conjugate
was added to each well. This was followed by 2 hours of incubation at room temperature. The
solution was decanted from the wells and the plate was washed 3 times. Then 100 µL of chromogen
solution was added into each well within 15 minutes of the washing step, followed by 30 min of
incubation time in the dark at room temperature. At the end, 100 µL of stop solution was added
into each well and absorbance was read by a plate reader at 450 nm wavelength.

Figure 2-1: Step-by-step process of ELISA sandwich formation
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2.3 Identification of SNPs in TNFα, TNFRSF1A, and TNFRSF1B genes
Purification of genomic DNA was done from peripheral blood leukocytes using QIAamp
DNA Blood Mini Kit (Qiagen) following manufacturer’s instructions. TaqMan genotyping
assays (Applied Biosystems) for TNFα rs1800629, TNFRSF1A rs767455, and TNFRSF1B
rs3397 were performed on isolated DNA samples following manufacturer protocol at the
University of Florida Pharmacotherapy and Translational Research Department (Gainesville,
FL). 2x TaqMan master mix and 20x assay working stock (primers with VIC and FAM
fluorophore attachment) made up the reaction mixture. Following Reverse Transcription
Polymerase Chain Reaction (RT-PCR) assay (one cycle at 95oC for 10 min, 92oC for 15 s and 50
cycles at 58oC for 1 min), isolated DNA samples along with reaction mixture and controls were
added into a 384-well micro-titre plate using Applied Biosystems QuantStudio RT-PCR System.
The plate was analysed for VIC and FAM fluorophores at 551 and 517 nm, respectively.
Fluorescence of VIC or FAM alone determined that the sample had allele 1 or allele 2, while
VIC and FAM together determined that the sample was heterozygous for each allele.
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CHAPTER 3. RESULTS
3.1 MAP and Osteocalcin
This chapter presents the findings of the research conducted. The main research objectives of
the study are examined and illustrated with data and information that have been gathered.
Active osteocalcin levels of RA patients (2.70 ± 0.87 ng/mL) were significantly lower than
healthy controls (5.84 ± 1.42 ng/mL, P-values < 0.05) as shown in table 3-1 and figure 3-1. This
is expected because patients with RA have a decrease in activity of osteoblast, which leads to less
synthesis of osteocalcin, and hence the presence of osteoporosis.
Table 3-1: Average Active Osteocalcin levels for RA and Healthy patients

Figure 3-1: Column graph of Average Active Osteocalcin levels for RA and Healthy patients
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Regardless of diagnosis, patients that were MAP+ had a significantly lower level of active
osteocalcin (0.66 ± 0.29 ng/mL) in comparison to MAP- negative patients (4.95 ± 0.98 ng/mL, Pvalues < 0.05). This is important, in that, the following results in Table 3-2 and Figure 3-2 suggests
that there seems to be a downregulation in the level of active osteocalcin in the presence of MAP.
Table 3-2: Average Active Osteocalcin levels for MAP- vs. MAP+ patients

Figure 3-2: Column graph of Average Active Osteocalcin levels for MAP- vs. MAP+ patients

In terms of the RA and Healthy patients, active osteocalcin levels were higher in MAP
positive patients whereas MAP negative patients’ active osteocalcin levels were lower. MAP
negative RA patients had an average active osteocalcin level of 3.85 ± 1.31 ng/mL vs. 0.60 ± 0.31
ng/mL of MAP positive RA patients. Healthy MAP positive patients had an active osteocalcin
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level of 1.647 ng/mL vs. 5.966 ± 8.31 ng/mL of MAP negative healthy patients, as shown in Table
3-3 and figure 3-3.
Table 3-3: Average Active Osteocalcin levels for MAP- vs. MAP+ in RA and MAP- vs. MAP+ in Healthy
patients

Figure 3-3: Column graph of Average Active Osteocalcin levels for MAP- vs. MAP+ in RA and MAP- vs.
MAP+ in Healthy patients

3.2 SNPs and Osteocalcin
When comparing RA to healthy patients, the active osteocalcin level for RA patients,
regardless of their genotype, was significantly lower than the active osteocalcin level of the
healthy patients as expected, shown in Table 3-4 and Figure 3-4. The active osteocalcin level for
RA patients without the TNFα:rs1800629 SNP who had the GG genotype (1.19 ± 0.39 ng/mL)
13

was higher than the RA patients who did not have the SNP and had the AA genotype. However,
there was no data for patients who had the SNP TNFα:rs1800629 with the AA genotype so this
comparison carried no significance.
Table 3-4: Average Active Osteocalcin levels for Healthy and RA patients with TNFα:rs1800629

Figure 3-4: Column graph of Average Active Osteocalcin levels for Healthy and RA patients with
TNFα:rs1800629

Just as Figure 3-4, Figure 3-5 shows that RA patients had a significantly lower level of
active osteocalcin than healthy patients, regardless of whether or not they had a the
TNFR1:rs767455 SNP. Table 3-5 shows patients with RA without the SNP who had the AA
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genotype (1.46 ± 0.53 ng/mL) had a higher level of active osteocalcin than RA patients with the
TNFR1:rs767455 SNP who had the GG genotype (1.54 ± 0.80 ng/mL). However, this
comparison did not yield any significance.
Table 3-5: Average Active Osteocalcin levels for Healthy and RA patients with TNFR1:rs767455

Figure 3-5: Column graph of Average Active Osteocalcin levels for Healthy and RA patients with
TNFR1:rs767455

Figure 3-6 shows that RA patients had a significantly lower level of active osteocalcin
than healthy patients, regardless of their whether or not they had the TNFR2:rs3397 SNP. When
comparing the active osteocalcin level between RA patients with the TNFR2:rs3397 SNP who
had the TT genotype and RA patients without the TNFR2:rs3397 SNP who had the CC
genotype, those with the SNP who had the TT genotype had a lower average active osteocalcin
15

level (0.98 ± 0.35 ng/mL) than those without the SNP who had the CC genotype (1.86 ± 0.61
ng/mL), as shown in Table 3-6.
Table 3-6: Average Active Osteocalcin levels for Healthy and RA patients with TNFR2:rs3397

Figure 3-6: Column graph of Average Active Osteocalcin levels for Healthy and RA patients with
TNFR2:rs3397
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CHAPTER 4. DISCUSSION
The long-term prognosis for individuals diagnosed with RA is very poor with, 80% of
individuals becoming disabled after 20 years and a life expectancy being reduced from 3 to 18
years [37]. Besides the usual complications with RA, like osteoporosis and rheumatoid nodules,
individuals with RA can develop heart problems as a result of blocked or hardened arteries or
inflammation of the sac that encloses the heart. Other complications that may arise from severe
RA are lung disease from the scarring of lung tissues and carpal tunnel syndrome [38]. These
complications are derived from the fact that as a result of a deficiency of vitamin K, there will be
a presence of osteoporosis and an increase in inflammation of the joints, both common
symptoms and signs of RA.
MAP is known to have a microbial effect on the development and susceptibility of CD
[28] [29] [39]. Since CD and RA are autoimmune diseases that share similar pathologies, the
level of active osteocalcin was used to determine whether MAP is a pathological element in RA.
In CD, it was found that following MAP infection, the average level of Y-carboxylated
osteocalcin decreased and the average level of ucOC increased in human samples [29]. Knowing
that the level of unOC increased in human samples, it was hypothesized that the level of active
osteocalcin would decrease.
The question of whether or not the genomic frequencies of TNFα, TNFRSF1A, and
TNFRSF1B played a role in level of active osteocalcin in RA patients was also brought up. In a
previous study, patients that had the TNFα:rs1800629 SNP had a higher susceptibility to CD.
The TNFR1:rs767455 and TNFR2:rs3397 SNPs found in patients were used to predict antiTNFα response in CD [31].
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CHAPTER 5. CONCLUSIONS AND FUTURE DIRECTIONS
This chapter provides an overview of this dissertation, a summary of the final results and
findings, conclusions, and directions for future research.
In summation, individuals who have RA tend to have low synthesis of active osteocalcin
in the body. Active osteocalcin levels of RA patients were significantly lower than healthy
controls. In terms of RA patients, active osteocalcin levels were decreased in MAP positive
patients whereas MAP negative patients’ active osteocalcin levels were decreased. When looking
at healthy controls, MAP positive healthy patients had a lower average active osteocalcin level in
comparison to MAP negative healthy patients. The downregulation of active osteocalcin in
correlation to the presence of MAP in RA individuals supports a role of MAP as a pathogenesis
element in RA.
In addition, SNPs, TNFα:1800629 and TNFRSF1A:767455, did not significantly affect
the level of active osteocalcin in RA. However, those who had the SNP TNFRSF1B:rs3397 with
TT genotype had a lower level of active osteocalcin than the CC genotype. Overall, there is a
correlation between the presence of SNPs in TNFα, TNFRSF1A, and TNFRSF1B and the
downregulation of active osteocalcin in RA patients.
Future research may involve looking at other bone markers, such as undercarboxylated
osteocalcin, to see correlation between MAP infection and RA and osteoporosis.
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